Exploring the Role of Benchmarking in AI/ML for Antibody Discovery and Engineering

his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo Nordisk take on where AI/ML has the biggest impact, what the hype is in the use of AI/ML in antibody discovery, how new AI/ML methods are being benchmarked against traditional discovery methods, and what controls should be used in an AI/ML discovery or optimization campaign.